Sublingual Tizanidine HCl
Protocol C2/5/TZ-TBI-01
Phase 1 small_molecule completed
Quick answer
Sublingual Tizanidine HCl for Traumatic Brain Injury is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Traumatic Brain Injury
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed